Nebraska is currently home to 726 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Omaha, Lincoln, Kearney and Grand Island. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease
NCT06319339
Recruiting
Peripheral artery disease (PAD) is associated with elevated oxidative stress, and oxidative stress has been implicated as the cause of reduced endothelial reactivity in individuals with PAD. Endothelial function is important because the endothelium contributes to the dilation of arteries during exercise, thereby implicating impaired endothelial function as a mechanism contributing to exacerbated exercise-induced ischemia. Therefore, the purpose of this study is to test the hypothesis that acute... Read More
Gender:
ALL
Ages:
Between 50 years and 75 years
Trial Updated:
03/26/2025
Locations: University of Nebraska - Omaha, Omaha, Nebraska
Conditions: Peripheral Artery Disease, Peripheral Vascular Diseases, Peripheral Arterial Disease, Peripheral Arterial Occlusive Disease
Register for Updates
An INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY to ASSESS the PERFORMANCE of the CORDIO HEARO SYSTEM
NCT06378632
Recruiting
Study Design: This is an international, multicenter, observational, non-interventional, prospective, blinded, single-arm, two-period study, to collect patient utterances that will be retrospectively analyzed to determine the sensitivity and UPNR of the HearO system.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/25/2025
Locations: Nebraska Heart Center, Lincoln, Nebraska
Conditions: Heart Failure
Register for Updates
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589
Recruiting
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/24/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Cystic Fibrosis
Register for Updates
First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants
NCT06673667
Recruiting
This is a first-in-human study to evaluate safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-621 in healthy male and female adult participants.
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
03/21/2025
Locations: Celerion, Lincoln, Nebraska
Conditions: Healthy Participants Study
Register for Updates
Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05467891
Recruiting
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Register for Updates
A Study of YL201 in Patients with Advanced Solid Tumors
NCT05434234
Recruiting
This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Advanced Solid Tumor
Register for Updates
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
NCT06864143
Recruiting
The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/19/2025
Locations: Velocity Clinical Research, Norfolk, Norfolk, Nebraska
Conditions: Influenza, SARS-CoV-2
Register for Updates
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
NCT04729114
Recruiting
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their cancer has come back after previous cancer treatment, or the previous cancer treatment they had didn't work. The main aims of the study are: * to check the safety of PRL-02 depot given with and without... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: XCancer Center Omaha/Urology Cancer Center, Omaha, Nebraska
Conditions: Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Register for Updates
Enhancing Uptake of Preconception Care Services in Family Practice Clinics Using a Patient Centered Screening Tool
NCT06582160
Recruiting
Sixteen years have passed since the Centers for Disease Control recommended routine preconception screening and counseling in primary care settings, yet time constraints and low preconception counseling adherence have prevented widespread uptake. This innovative, self-selected preconception screening tool encourages participants to be active in their own care and eliminates the time burden associated with typical pre-selected screening in clinics. This project will generate important knowledge a... Read More
Gender:
FEMALE
Ages:
Between 19 years and 49 years
Trial Updated:
03/17/2025
Locations: Nebraska Medicine - Fontenelle Clinic, Omaha, Nebraska
Conditions: Women, Reproductive Age
Register for Updates
Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
NCT05917522
Recruiting
800 adult first time kidney transplant recipients will be enrolled in the Observational Study and followed to evaluate their Human Leukocyte Antigen (HLA)-DR/DQ molecular mismatch (mMM) score as a risk-stratifying prognostic biomarker. Six months after transplant the study will identify those who meet the eligibility criteria for the Nested Randomized Control Trial (RCT). 300 eligible subjects will be randomized 2:1 to abatacept or Standard of care (SOC) in the randomization and followed for 18... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/17/2025
Locations: University of Nebraska Medical Center: Transplantation, Omaha, Nebraska
Conditions: Kidney Transplant
Register for Updates
Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years with ADHD
NCT06431256
Recruiting
This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD.
Gender:
ALL
Ages:
Between 4 years and 5 years
Trial Updated:
03/14/2025
Locations: HLD200-112 Study Site, Lincoln, Nebraska
Conditions: Attention Deficit Hyperactivity Disorder
Register for Updates
Efficacy Evaluation of Using Finger Stick Peripheral Blood for Point of Care Pregnancy Testing
NCT06747598
Recruiting
To evaluate the efficacy of using peripheral blood for POC pregnancy testing in known pregnant participants.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
03/13/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Pregnancy Testing
Register for Updates